Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

Toshiharu Okuda

    Clinical Calcium
    |March 19, 2005
    PubMed
    Summary

    Monitoring bone resorption (deoxypyridinoline) and bone formation (bone alkaline phosphatase) markers helps assess osteoporosis treatment efficacy with alendronate therapy.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    [The frontier of adipocyte biology, cold environment induces thermogenic genes via epigenomic switch.]

    Clinical calcium·2019
    Same journal

    [Sequential treatment of osteoporosis with anti-sclerostin.]

    Clinical calcium·2019
    Same journal

    [The sequential therapy of romosozumab followed by denosumab for osteoporosis.]

    Clinical calcium·2019
    Same journal

    [Wnt signaling in myeloma.]

    Clinical calcium·2019
    Same journal

    [Fate decision of hematopoietic stem cells by Wnt signaling.]

    Clinical calcium·2019
    Same journal

    [Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]

    Clinical calcium·2019

    Area of Science:

    • Biochemistry
    • Orthopedics
    • Pharmacology

    Context:

    • Osteoporosis management requires effective treatment monitoring.
    • Alendronate is a common osteoporosis medication.
    • Bone turnover markers provide insights into treatment response.

    Purpose:

    • To evaluate the utility of bone resorption and formation markers in assessing alendronate therapy for osteoporosis.
    • To determine the time course of marker changes during alendronate treatment.

    Summary:

    • Urinary deoxypyridinoline (DPD) and serum bone alkaline phosphatase (BAP) were measured in three osteoporotic patients on alendronate.
    • DPD levels decreased within 1-2 months, while BAP levels decreased by 30-40% within 3 months.
    • These findings indicate significant changes in bone turnover markers following alendronate initiation.

    Impact:

    • Bone turnover markers are valuable tools for selecting appropriate osteoporosis medications.
    • Early assessment of treatment efficacy can be achieved through monitoring DPD and BAP levels.
    • This study supports the use of biochemical markers for personalized osteoporosis treatment strategies.